公开(公告)号：US20180155385A1

公开(公告)日：2018-06-07

申请号：US15576948

申请日：2016-05-23

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Cyril B. DOUSSON ,  David DUKHAN ,  Christophe Claude PARSY

IPC: C07H19/11 ,  A61P35/00

Abstract: The present invention relates to novel nucleoside derivatives, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.

公开(公告)号：US20180258130A1

公开(公告)日：2018-09-13

申请号：US15981813

申请日：2018-05-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Benjamin Alexander MAYES ,  Adel M. MOUSSA ,  Alistair James STEWART ,  Gilles GOSSELIN ,  Christophe Claude PARSY ,  François-René ALEXANDRE ,  Jean-François GRIFFON ,  Dominique SURLERAUX ,  Cyril B. DOUSSON ,  Claire PIERRA ,  Houcine RAHALI

IPC: C07H19/20 ,  C07H19/10 ,  A61K31/403 ,  C07H19/16 ,  A61K38/55 ,  A61K38/21 ,  A61K31/7056 ,  A61K31/708 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/7072 ,  A61K31/4709 ,  A61K31/497

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

公开(公告)号：US20160002281A1

公开(公告)日：2016-01-07

申请号：US14856462

申请日：2015-09-16

Applicant: Idenix Pharmaceuticals LLC

Inventor： Benjamin Alexander MAYES ,  Adel M. MOUSSA ,  Alistair James STEWART ,  Gilles GOSSELIN ,  Christophe Claude PARSY ,  François-René ALEXANDRE ,  Jean-François GRIFFON ,  Dominique SURLERAUX ,  Cyril B. DOUSSON ,  Claire PIERRA ,  Houcine RAHALI

IPC: C07H19/20 ,  C07H19/10

CPC classification number: C07H19/20 ,  A61K31/403 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/55 ,  A61K45/06 ,  C07H19/10 ,  C07H19/16 ,  A61K2300/00

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.